The effect of antiviral therapy on the prognosis of patients with HBV-DNA-negative hepatitis B-related hepatocellular carcinoma after hepatectomy: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058194

Enrollment

Unknown

Registered

2022-04-01

Start date

2022-05-01

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Trial Group :Postoperative TDF treatment

Control Group :No antiviral therapy after surgery

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-70 Years old; 2. First diagnosis of hepatocellular carcinoma; 3. Receiving radical surgery; 4. BCLC stage 0 or A; 5. Preoperative HBV-DNA 60 min) /ml); 9. ECOG-Score 0; 10. Understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with recurrence of hepatocellular carcinoma; 2. Combined with macrovascular invasion; 3. Combined with HCV, HIV infection, or other serious infections; 4. Combined with other malignant tumors; 5. Combined with psychiatric disorders; 6. Patients who participated in other clinical trials in the last three months; 7. Patients with severe non-tumor-related diseases; 8. Received anti-tumor therapy before surgery; 9. Received anti-viral therapy in the past.

Design outcomes

Primary

Measure	Time frame
recurrence-free survival;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactChuan Li

West China Hospital of Sichuan University

lichuan85@163.com+86 18980606853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026